Showing results (131-140 of 496) with videos related to
Sort By:
Pageof 50
Biogerontology|November 16, 2001
AGES in brain ageing: AGE-inhibitors as neuroprotective and anti-dementia drugs?S Dukic-Stefanovic, R Schinzel, P Riederer, et al.Journal of Neural Transmission|January 1, 1975
The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, DeprenilW Birkmayer, P Riederer, M B Youdim, et al.Journal of Neural Transmission. Supplementum|January 1, 1995
Interaction of neuroprotective substances with human brain superoxide dismutase. An in vitro studyW Gsell, N Reichert, M B Youdim, et al.Neurotoxicology|December 31, 2003
Monoamine oxidase inhibition and CNS immunodeficiency infectionE Koutsilieri, C Scheller, V ter Meulen, et al.Arzneimittel-Forschung|February 1, 1992
Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophreniaP Riederer, K W Lange, J Kornhuber, et al.Brain Research|August 5, 1998
Advanced glycation endproducts are associated with Hirano bodies in Alzheimer's diseaseG Münch, A M Cunningham, P Riederer, et al.European Journal of Pharmacology|December 12, 1991
MPTP mechanisms of neurotoxicity and their implications for Parkinson's diseaseM Gerlach, P Riederer, H Przuntek, et al.Journal of Neural Transmission. Supplementum|January 1, 1991
Glutamate receptor antagonism: neurotoxicity, anti-akinetic effects, and psychosisP Riederer, K W Lange, J Kornhuber, et al.Journal of Neural Transmission. Supplementum|January 1, 1978
Brain monoamines in hepatic encephalopathy and other types of metabolic comaK Jellinger, P Riederer, W D Rausch, et al.Journal of Neural Transmission. Supplementum|January 1, 1995
Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders?D Blum-Degen, L Frölich, S Hoyer, et al.Pageof 50